Coagulation monitoring

More efficiency in my care facility. More freedom for my patients

Quality care for your patients taking vitamin K antagonists

Vitamin K antagonists (VKAs) require close monitoring because of individual variations, drug-drug or food-drug interactions. Studies have shown that increasing a patient’s time in therapeutic range, as measured by their international normalised ratio (INR) value, maximises the benefits of anticoagulation therapy and minimises the risk of thromboembolic events.^1-3 Therefore, keeping careful track of your patient's INR value to ensure it is in the optimal therapeutic range is critical.

Models of patient monitoring

A variety of models exists for managing patients of VKA therapy. Learn more about the benefits of point of care and patient self-testing and how we can support you in selecting the right model for you and your patients.

For more information

Enhance efficiency for you and freedom for your patient

Traditional or usual care

Performed by a conventional laboratory. Results can take hours if not overnight to be returned to the physician. The healthcare professional interprets the result and, if needed, changes the patient’s dosage. The patient may have to wait for the results, or even return to the physician after the result is delivered.

Point of care testing

Performed by healthcare professionals immediately at the patient point of care. CoaguChek offers reliable and easy to use solutions that provide immediate results. Thus, allowing treatment decisions to be made more quickly.

Patient self-testing

Together with you, properly trained patients and/or caregivers are capable of performing reliable INR testing themselves. This method of coagulation monitoring may provide some patients with the maximum amount of freedom to suit their testing needs.

References

Yi Wan & al.- Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibril (v1.0) Anne Holbrook, Sam Schulman, Daniel M. Witt, Per Olav Vandvik-Evidence- Based Management of Anticoag (v1.0) Katherine W Phillips and Jack Ansell-Outpatient management of oral vitamin K antagonist therapy: def (v1.0)
Wan et al. (2008). Circ Cardiovasc Qual Outcomes 1, 84–91
Holbrook et al. (2012). Chest 141, e152S–e184S